| 000 | 018170000a22003490004500 | ||
|---|---|---|---|
| 003 | EG-GICUC | ||
| 005 | 20250223030818.0 | ||
| 008 | 060917s2006 ua a f m 000 0 eng d | ||
| 040 |
_aEG-GICUC _beng _cEG-GICUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.08.09.M.Sc.2006.Mo.E | ||
| 100 | 0 | _aMona Mohamed Kamal | |
| 245 | 1 | 0 |
_aEffect of P - glycoprotein blockers on the bioavailability of paclitaxel in experimental animals / _cMona Mohamed Kamal ; Supervised Mohamed Taki Eldeen Khayyal , Mahmoud Mohamed Merzabani , Abdelmoneim Mahmoud Osman |
| 246 | 1 | 5 | _aتاثير مثبطات البى - جليكوبروتين على النشاط الحيوى لعقار الباكليتاكسيل فى حيوانات التجارب |
| 260 |
_aCairo : _bMona Mohamed Kamal , _c2006 |
||
| 300 |
_a85 P. : _bill ; _c30cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology | ||
| 520 | _aPaclitaxel (Taxol) is an antineoplastic agent used to treat many types of cancer poor oral absorption and consequently poor bioavailability The poor oral bioavailability results mainly from the activity of the P - glycoprotein (P - gp) efflux pump multi - drug Cyclosporine (an immunosuppressive drug) and verapamil (a calcium channel blocker) were used in this study as examples of P - gp efflux pump blockers | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aP-glycoprotein | |
| 653 | 4 | _aPaclitaxel | |
| 653 | 4 | _aVerapamil | |
| 700 | 0 |
_aAbdelmoneim Mahmoud Osman , _eSupervisor |
|
| 700 | 0 |
_aMahmoud Mohamed Merzabani , _eSupervisor |
|
| 700 | 0 |
_aMohamed Taki Eldeen Khayyal , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aMustafa _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c42444 _d42444 |
||